companies / betaglue-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 33,580,00033.6M | ○ |
|---|---|---|
| founded | 2009 | |
| hq | Milan, Italy | |
| industry | unknown | |
| stage | null |
BetaGlue Therapeutics develops targeted nuclear medicine for solid tumors, led by YntraDose, an Yttrium-90 microsphere radiotherapy delivered directly into the tumor. It serves cancer patients with hard-to-treat solid tumors such as locally advanced pancreatic cancer and hepatocellular carcinoma. Its interventional approach concentrates radiation inside the tumor to spare healthy tissue compared with external-beam radiotherapy.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-04-01 | grant | 2,700,0002.7M | null | ○ |
WordPress 7.0, Yoast SEO 27.4, reCAPTCHA, jQuery Migrate 3.4.1, PHP, cdnjs, Contact Form 7 6.1.5, Python, Cloudflare, MySQL, jquery 3.7.1
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |